Get notified when ALZN files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Going Concern (new) — The auditor's report includes a going-concern explanatory paragraph, signaling substantial doubt about the company's ability to continue operating.
Alzamend Neuro files to sell up to $3M of common stock in at-the-market offering
Filed March 6, 2026 · ~1 min read
Key Changes
-
high
Alzamend Neuro may sell up to $3,000,000 of common stock from time to time through sales agent Ascendiant Capital Markets.
The Offering verify on EDGAR → -
medium
The offering is at-the-market, with no minimum amount required; shares will be sold at prevailing market prices, which were $1.95 on March 5, 2026.
The Offering verify on EDGAR → -
medium
Net proceeds are earmarked for general corporate purposes, including working capital, R&D, clinical trials, and potential acquisitions, with broad management discretion.
Use of Proceeds verify on EDGAR →
1 more material change behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (PANW 10-K) is open in full — no account needed.
Partner
Trade ALZN commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 2, 2026 · How we verify